hero image
Jatinder Lamba - University of Florida. Gainesville, FL, US

Jatinder Lamba Jatinder Lamba

Professor/Chair | University of Florida

Gainesville, FL, UNITED STATES

Jatinder Lamba focuses on genomic/epigenomic markers predictive of therapeutic outcome in cancer patients.

Biography

Jatinder Lamba’s research is focused on identification, characterization and clinical validation of genomic/epigenomic markers predictive of therapeutic outcome in cancer patients. This research spans from preclinical basic research comprising the discovery phase utilizing cell line model systems to translational/clinical phase in patient populations from multi-institute clinical trials. The long-term goal of her research is to move pharmacogenetic testing into the clinical setting to improve safety and efficacy of drug therapy.

Areas of Expertise (4)

Acute Myeloid Leukemia

Pharmacogemonics

Pharmacogenetics

Precision Medicine

Media Appearances (2)

Polygenic Score Helps Guide Choice of Chemo for Pediatric AML

News-Herald  print

2022-02-01

A polygenic score derived from pharmacogenomic evaluation of cytarabine (ara-C) pathway can help personalize treatment for pediatric patients with acute myeloid leukemia (AML), according to a study published online Jan. 18 in the Journal of Clinical Oncology.

view more

New study allows UF Health researchers to customize treatments for children with cancer

WCJB 20  tv

2022-01-14

In a study published in the journal of clinical oncology, researchers figured out how to make sure each child dealing with cancer gets the appropriate amount of chemotherapy based on the score assigned to each patient based on their genetic make-up.
 They then were able to determine who would respond best to chemotherapy.

view more

Articles (3)

Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation

Journal of Clinical Oncology

Elsayed H. Abdelrahman et al.

2022-01-06

To establish a patient-specific polygenic score derived from cytarabine (ara-C) pathway pharmacogenomic evaluation to personalize acute myeloid leukemia (AML) treatment.

view more

Building a precision oncology workforce by multidisciplinary and case-based learning

BMC Medical Education

Chamala Srikar, et al.

2021-01-26

Participants in two recent National Academy of Medicine workshops identified a need for more multi-disciplinary professionals on teams to assist oncology clinicians in precision oncology. We developed a graduate school course to prepare biomedical students and pharmacy students to work within a multidisciplinary team of oncology clinicians, pathologists, radiologists, clinical pharmacists, and genetic counselors.

view more

Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML

Hematologic Malignancies

Bradley Stockard, et al.

2021-06-10

Acute myeloid leukemia (AML) is a hematological malignancy with a dismal prognosis. For over four decades, AML has primarily been treated by cytarabine combined with an anthracycline. Although a significant proportion of patients achieve remission with this regimen, roughly 40% of children and 70% of adults relapse. Over 90% of patients with resistant or relapsed AML die within 3 years.

view more

Languages (1)

  • English